Drug intelligence / Profile preview

osmundacetone

Development stage: Preclinical
Modality: Small Molecules

Overview

Osmundacetone (OSC) is a bioactive phenolic compound isolated from the medicinal mushroom *Phellinus igniarius*. It exhibits potent antiproliferative and cytotoxic effects against non-small cell lung cancer (NSCLC) cells. The drug's mechanism of action centers on the downregulation of glutamate dehydrogenase 1 (GLUD1), a key enzyme in glutamine metabolism. By inhibiting the glutamine/glutamate/α-ketoglutarate (α-KG) metabolic axis, osmundacetone disrupts mitochondrial oxidative phosphorylation (OXPHOS) and reduces ATP production. This metabolic modulation leads to G2/M cell cycle arrest and suppression of tumor growth, as demonstrated in both in vitro and in vivo xenograft models.

Other names: 4-(3,4-dihydroxyphenyl)-3-buten-2-one4-(3,4-dihydroxyphenyl)but-3-en-2-one

Targets

GLUD1 (Glutamate dehydrogenase 1, mitochondrial)

Beyond the preview

Go deeper on osmundacetone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on osmundacetone.

Explore the full profile